Research and Markets: Nuclear Oncology Covers Imaging, Dosimetric, And Therapeutic Applications of Radiopharmaceuticals and Metabolic Imaging Agents

DUBLIN-(Business Wire)-September 24, 2009 - Research and Markets(http://www.researchandmarkets.com/research/03c458/nuclear_oncology) has announced the addition of the "Nuclear Oncology" training to their offering.

The Johns Hopkins University School of Medicine

Genetic alterations often indicate the risk of developing cancer and can define molecular signatures suitable for radionuclide diagnosis and therapy. Once identified, they can be targets for stable or radioactive pharmaceuticals to try to bring about complete or partial remission of the patient's disease. This program in Nuclear Oncology covers imaging, dosimetric, and therapeutic applications of radiopharmaceuticals and metabolic imaging agents, with descriptions of how these techniques are being applied in the care of patients. The integration of imaging to personalized treatment choices is also emphasized.

Target Audience

This program will have special relevance for nuclear medicine physicians, radiologists, and radiation oncologists, and will also be useful for all who treat patients with cancer.

Learning Objectives

At the conclusion of this program, participants should be able to:

Improve their ability to treat patients with Lymphoma
Select appropriate therapy for a variety of tumors
Describe particular advantages of alpha therapy
Describe current and future directions of research

Accreditation Statement

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 9.70 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Speaker and Provider Disclosure

It is the policy of The Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity electronic syllabus. The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

Release date: July 15, 2008 Credits expire: June 15, 2011

CME credit is obtained upon successful completion of an activity evaluation. A processing fee must accompany the completed evaluation application.

Key Topics Covered:

Topics & Speakers

From Molecular Imaging to Molecular Medicine
Henry N. Wagner, Jr., MD
The Role of Genes in Cancer
Will Parsons, MD, PhD
The Radiobiology of Cancer Therapy
Fred Bunz, MD, PhD

Lymphoma

Radioimmunotherapy: Last Resort or First Choice
Mark S. Kaminski, MD
PET/CT to Plan Therapy
Yvette L. Kasamon, MD
SPECT/CT to Plan Therapy
Richard L. Wahl, MD
Quantitative Data from SPECT/CT
Benjamin M. W. Tsui, PhD

Thyroid Cancer

Update on Dosimetry-Based Techniques
George Sgouros, PhD
Molecular Basis for Thyroidal Radioiodine Avidity and Its Loss in Thyroid Cancer Cells
Paul W. Ladenson, MD
Neuroendocrine Tumors
Experience with MIBG
Alexander J.B. McEwan, MD
Radiopeptides as Therapeutic Agents
Otto C. Boerman, PhD

Solid Tumors

90Y-Microspheres for Liver Tumors
Jeff H. Geschwind, MD
RIT for Pancreatic Cancer
David M. Goldenberg, SCD, MD
RIT for Colon and Renal Cancers
Chaitanya R. Divgi, MD
Early Experience Using Peptide Targeted Radionuclide Therapy in Patients with Lung Cancer
John Lister-James, PhD
Control of the Expression of the Genotype
Stephen B. Baylin, MD
Brain Tumors, Sarcoma, and Bone Metastase
131I-Scorpion Venom Toxin for Treatment of Brain Tumors
Heather A. Jacene, MD
Sarcoma
David M. Loeb, MD, PhD
Metastatic Bone Disease
Alexander J.B. McEwan, MD

Therapy with Alpha Particles

Dosimetry
George Sgouros, PhD
Experience with Radium-223 in the Treatment of Patients with Skeletal Metastases
Peter A. Harris, MBBS, FFPM
Actinium-225 and Bismuth-213 for Leukemia
David A. Scheinberg, MD, PhD
Astatine-211 Labeled Radiopharmaceuticals
Ganesan Vaidyanathan, PhD

Prospects for the Future

Translating Radiopharmaceuticals from the Laboratory to the Clinic
George Q. Mills, MD
Pretargeting with Bispecific Antibodies
Otto C. Boerman, PhD
New Ligands and Approaches to Radionuclide Imaging and Therapy
Martin G. Pomper, MD, PhD
Integration of Radionuclide Therapy into Multidisciplinary Treatment of Solid Tumors
Chaitanya R. Divgi, MD

Course Director